Search results for “Anti-Epidermal Growth Factor Receptor Antibody” companies
Free sign up to view the full data
Key Players
Order by:
Innovation Intensity
With the analysis among 158 patents, we discovered top 20 key players by total patent application. AbbVie, Inc., Halozyme, Inc., Symphogen A/S are dominant in this area. They take 57.59% of the total patent filing.
Illinois, United States
Patent: 35
California, United States
Patent: 29
Hovedstaden, Denmark
Patent: 27
New York, United States
Patent: 13
France
Patent: 12
Shanghai Shi, China
Patent: 8
Hessen, Germany
Patent: 7
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
Jiangsu Sheng, China
Patent: 5
Cuba
Patent: 4
Shanghai Shi, China
Patent: 3
Startups & Unicorns
Order by:
Innovation Intensity
No data, please try another search term
Fast-Growing
Order by:
Innovation in recent 5 years
With the analysis among related 24 patents applied in the last 5 years. We discover 6 most active companies in this area. The fast-growing AbbVie, Inc., Amgen, Inc., Shanghai Henlius Biotech, Inc. take 91.67% of patent filing during this period.
Illinois, United States
Patent: 18
California, United States
Patent: 2
Shanghai Shi, China
Patent: 2
New York, United States
Patent: 1
Hessen, Germany
Patent: 1
Shanghai Shi, China
Patent: 1
New Entrants
Order by:
Innovation in recent 5 years
With the analysis among related 24 patents in last 5 years, we discover 3 new entrants.
California, United States
Patent: 2
New York, United States
Patent: 1
Hessen, Germany
Patent: 1
Research Institutions
Order by:
Innovation Intensity
No data, please try another search term
Keywords Quick Entry
Popular
Physics
Chemistry
Engineering
Materials science
Computer science
Biology
Medicine
MetalElectrodeVoltageSemiconductorPolymerElectricityCoatingFiberDisplay deviceRaw materialElectric motorUltimate tensile strengthNozzleCarbonBuilding constructionAlkylService lifeElectronOxideOxygenSolventControl unitFlangeControl systemDrugLight sourcePistonDiseaseElectric powerHigh pressure
View more
Page generation time: